Valuation Aligned Genetics, Inc.
Stocks
A238120
KR7238120000
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,015.00 KRW | -1.63% |
|
-2.11% | -22.09% |
| 11-14 | ACS, BlackRock launch 2 billion euro data centre joint venture | RE |
| 11-13 | ACS, BlackRock to seal $27 billion data centre deal, report says | RE |
Company Valuation: Aligned Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 71,176 | 61,614 | 54,137 | 57,947 | 43,496 | 54,406 |
| Change | - | -13.43% | -12.14% | 7.04% | -24.94% | 25.08% |
| Enterprise Value (EV) 1 | 60,165 | 52,912 | 44,820 | 47,683 | 28,821 | 54,293 |
| Change | - | -12.05% | -15.29% | 6.39% | -39.56% | 88.38% |
| P/E | 110x | 11.1x | 23.2x | 17.9x | 10.5x | 18.8x |
| PBR | 3.32x | 2.28x | 1.88x | 1.85x | 1.23x | 1.46x |
| PEG | - | 0x | -0.4x | 0.5x | 0.4x | -0.7x |
| Capitalization / Revenue | 8.94x | 5.24x | 3.94x | 3.81x | 2.76x | 3.4x |
| EV / Revenue | 7.56x | 4.5x | 3.26x | 3.13x | 1.83x | 3.39x |
| EV / EBITDA | 142x | 19.5x | 12.8x | 12x | 8.59x | 17.8x |
| EV / EBIT | -237x | 24.3x | 15.7x | 14.3x | 10.4x | 22.2x |
| EV / FCF | 174x | -19.8x | -115x | 50.3x | 25.9x | -5.96x |
| FCF Yield | 0.57% | -5.06% | -0.87% | 1.99% | 3.86% | -16.8% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 45 | 385.4 | 162 | 225 | 287 | 206.2 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 7,957 | 11,762 | 13,753 | 15,215 | 15,778 | 16,016 |
| EBITDA 1 | 422.6 | 2,718 | 3,499 | 3,968 | 3,355 | 3,052 |
| EBIT 1 | -253.5 | 2,179 | 2,849 | 3,337 | 2,780 | 2,443 |
| Net income 1 | 468.2 | 5,542 | 2,333 | 3,236 | 4,128 | 2,911 |
| Net Debt 1 | -11,010 | -8,701 | -9,317 | -10,264 | -14,676 | -113 |
| Reference price 2 | 4,950.00 | 4,285.00 | 3,765.00 | 4,030.00 | 3,025.00 | 3,870.00 |
| Nbr of stocks (in thousands) | 14,379 | 14,379 | 14,379 | 14,379 | 14,379 | 14,058 |
| Announcement Date | 3/19/21 | 3/4/22 | 3/10/23 | 3/6/24 | 3/11/25 | 3/19/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 29.84M | |
| 60.6x | 4.61x | 15.43x | 0.36% | 15.54B | |
| 38.39x | - | - | 2.11% | 1.65B | |
| -10.03x | 1.28x | 5.61x | -.--% | 1.09B | |
| 15.99x | 2.25x | 7.53x | 1.47% | 948M | |
| 49.42x | - | - | 0.91% | 505M | |
| 46.97x | - | - | - | 460M | |
| 17.87x | 2.51x | 10.73x | 1.91% | 365M | |
| 24.01x | 4.07x | 13.86x | 1.96% | 344M | |
| Average | 30.40x | 2.94x | 10.63x | 1.24% | 2.33B | |
| Weighted average by Cap. | 51.21x | 4.23x | 14.31x | 0.6% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A238120 Stock
- Valuation Aligned Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
